-
2
-
-
0019799332
-
A method for estimating the probability of adverse drug reactions
-
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
-
(1981)
Clin Pharmacol Ther
, vol.30
, pp. 239-245
-
-
Naranjo, C.A.1
Busto, U.2
Sellers, E.M.3
Sandor, P.4
Ruiz, I.5
Roberts, E.A.6
-
3
-
-
0021327806
-
Neuroleptics as causes of oculogyric crises
-
Dorevitch A. Neuroleptics as causes of oculogyric crises. Arch Neurol 1984;41:15-6.
-
(1984)
Arch Neurol
, vol.41
, pp. 15-16
-
-
Dorevitch, A.1
-
4
-
-
0025236537
-
Dystonia - A potential psychiatric pitfall
-
Owens DGC. Dystonia - a potential psychiatric pitfall. Br J Psychiatry 1990;156:620-34.
-
(1990)
Br J Psychiatry
, vol.156
, pp. 620-634
-
-
Owens, D.G.C.1
-
5
-
-
0016812228
-
Drug-induced dystonia
-
Swett C. Drug-induced dystonia. Am J Psychiatry 1975;132:532-4.
-
(1975)
Am J Psychiatry
, vol.132
, pp. 532-534
-
-
Swett, C.1
-
6
-
-
0024986447
-
Prevalence of neuroleptic-induced dystonia in mania and schizophrenia
-
Remington GJ, Voineskos G, Pollock B, Reed K, Coulter K. Prevalence of neuroleptic-induced dystonia in mania and schizophrenia. Am J Psychiatry 1990;147:1231-3.
-
(1990)
Am J Psychiatry
, vol.147
, pp. 1231-1233
-
-
Remington, G.J.1
Voineskos, G.2
Pollock, B.3
Reed, K.4
Coulter, K.5
-
7
-
-
0003174188
-
Practice guideline for the treatment of patients with schizophrenia
-
American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(suppl 4):1-63.
-
(1997)
Am J Psychiatry
, vol.154
, Issue.SUPPL. 4
, pp. 1-63
-
-
-
8
-
-
0022445363
-
Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: A prospective study
-
Sramek JJ, Simpson GM, Morrison RL, Heiser JF. Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study. J Clin Psychiatry 1986;47:305-9.
-
(1986)
J Clin Psychiatry
, vol.47
, pp. 305-309
-
-
Sramek, J.J.1
Simpson, G.M.2
Morrison, R.L.3
Heiser, J.F.4
-
9
-
-
0029930910
-
Circadian pattern of acute neuroleptic-induced dystonic reactions
-
Mazurek MF, Rosebush PI. Circadian pattern of acute neuroleptic-induced dystonic reactions. Am J Psychiatry 1996;153:708-10.
-
(1996)
Am J Psychiatry
, vol.153
, pp. 708-710
-
-
Mazurek, M.F.1
Rosebush, P.I.2
-
10
-
-
0009676668
-
Neuroleptic-induced acute dystonia
-
Lang AE, Weiner WJ, eds. New York: Futura Press
-
Casey DE. Neuroleptic-induced acute dystonia. In: Lang AE, Weiner WJ, eds. Drug-induced movement disorders. New York: Futura Press, 1991:21-40.
-
(1991)
Drug-induced Movement Disorders
, pp. 21-40
-
-
Casey, D.E.1
-
11
-
-
0032939740
-
Acute laryngeal dystonia related to neuroleptic agents
-
Fines RE, Brady WJ Jr, Martin ML. Acute laryngeal dystonia related to neuroleptic agents. Am J Emerg Med 1999;17:319-20.
-
(1999)
Am J Emerg Med
, vol.17
, pp. 319-320
-
-
Fines, R.E.1
Brady W.J., Jr.2
Martin, M.L.3
-
12
-
-
0025268175
-
Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment
-
World Health Organization Heads of Centres Collaborating in WHO coordinated studies on biological aspects of mental illness [letter]. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. Br J Psychiatry 1990;156:412.
-
(1990)
Br J Psychiatry
, vol.156
, pp. 412
-
-
-
13
-
-
0026410773
-
Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose
-
McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:739-45.
-
(1991)
Arch Gen Psychiatry
, vol.48
, pp. 739-745
-
-
McEvoy, J.P.1
Hogarty, G.E.2
Steingard, S.3
-
14
-
-
0016491711
-
Therapeutic reversal with benztropine in schizophrenics
-
Singh MM, Kay SR. Therapeutic reversal with benztropine in schizophrenics. J Nerv Ment Dis 1973;169:258-66.
-
(1973)
J Nerv Ment Dis
, vol.169
, pp. 258-266
-
-
Singh, M.M.1
Kay, S.R.2
-
15
-
-
0020967493
-
Adverse effects of anticholinergic medication on positive schizophrenic symptoms
-
Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DG, Bourne RC, et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 1983;13:513-27.
-
(1983)
Psychol Med
, vol.13
, pp. 513-527
-
-
Johnstone, E.C.1
Crow, T.J.2
Ferrier, I.N.3
Frith, C.D.4
Owens, D.G.5
Bourne, R.C.6
-
16
-
-
0027439488
-
Tardive and chronically recurrent oculogyric crisis
-
Sachdev P. Tardive and chronically recurrent oculogyric crisis. Move Disord 1993;8:93-7.
-
(1993)
Move Disord
, vol.8
, pp. 93-97
-
-
Sachdev, P.1
-
19
-
-
0021327806
-
Neuroleptics as causes of oculogyric crisis
-
Dorevitch A. Neuroleptics as causes of oculogyric crisis. Arch Neurol 1984;41:15-6.
-
(1984)
Arch Neurol
, vol.41
, pp. 15-16
-
-
Dorevitch, A.1
-
20
-
-
0033392246
-
Pharmacokinetics of haloperidol: An update
-
Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 1999;37:435-56.
-
(1999)
Clin Pharmacokinet
, vol.37
, pp. 435-456
-
-
Kudo, S.1
Ishizaki, T.2
-
22
-
-
0000340348
-
Parkinsonism-inducing neurotoxin N-methyl-1-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity
-
Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin N-methyl-1-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985;82:2173-7.
-
(1985)
Proc Natl Acad Sci USA
, vol.82
, pp. 2173-2177
-
-
Javitch, J.A.1
D'Amato, R.J.2
Strittmatter, S.M.3
Snyder, S.H.4
-
23
-
-
0003535402
-
-
Hudson, Ohio: Lexi-Comp
-
Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook. Hudson, Ohio: Lexi-Comp, 1999.
-
(1999)
Drug Information Handbook
-
-
Lacy, C.F.1
Armstrong, L.L.2
Goldman, M.P.3
Lance, L.L.4
-
24
-
-
0030722966
-
Metabolism of haloperidol to pyridium species in patients receiving high doses intravenously: Is HPTP an intermediate?
-
Avent KM, Riker RR, Fraser GL, van der Schyf CJ, Usuki E, Pond SM. Metabolism of haloperidol to pyridium species in patients receiving high doses intravenously: is HPTP an intermediate? Life Sci 1997;61:2383-90.
-
(1997)
Life Sci
, vol.61
, pp. 2383-2390
-
-
Avent, K.M.1
Riker, R.R.2
Fraser, G.L.3
Van der Schyf, C.J.4
Usuki, E.5
Pond, S.M.6
-
25
-
-
0028358360
-
Metabolism of haloperidol: Clinical implications and unanswered questions
-
Tsang MW, Shader RI, Greenblatt DJ. Metabolism of haloperidol: clinical implications and unanswered questions. J Clin Psychopharmacol 1994;14:159-62.
-
(1994)
J Clin Psychopharmacol
, vol.14
, pp. 159-162
-
-
Tsang, M.W.1
Shader, R.I.2
Greenblatt, D.J.3
-
27
-
-
0024513881
-
Dopamine receptor occupancy and plasma haloperidol levels
-
Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, et al. Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 1989;46:482-4.
-
(1989)
Arch Gen Psychiatry
, vol.46
, pp. 482-484
-
-
Wolkin, A.1
Brodie, J.D.2
Barouche, F.3
Rotrosen, J.4
Wolf, A.P.5
Smith, M.6
-
31
-
-
0022922096
-
Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study
-
McEvoy JP, Stiller RL, Farr R. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study. J Clin Psychopharmacol 1986;6:133-8.
-
(1986)
J Clin Psychopharmacol
, vol.6
, pp. 133-138
-
-
McEvoy, J.P.1
Stiller, R.L.2
Farr, R.3
-
32
-
-
0026410773
-
Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose
-
McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:739-45.
-
(1991)
Arch Gen Psychiatry
, vol.48
, pp. 739-745
-
-
McEvoy, J.P.1
Hogarty, G.E.2
Steingard, S.3
|